Skip to main content
Clinical Trials/NCT06003036
NCT06003036
Recruiting
N/A

Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment

Deepak K. Sarpal, M.D.1 site in 1 country30 target enrollmentDecember 1, 2023

Overview

Phase
N/A
Intervention
sham stimulation
Conditions
Schizophrenia
Sponsor
Deepak K. Sarpal, M.D.
Enrollment
30
Locations
1
Primary Endpoint
change in activation of the working memory network
Status
Recruiting
Last Updated
19 days ago

Overview

Brief Summary

In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that accelerated iTBS will enhance neurocognition relative to sham delivery.

Registry
clinicaltrials.gov
Start Date
December 1, 2023
End Date
July 1, 2026
Last Updated
19 days ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Deepak K. Sarpal, M.D.
Responsible Party
Sponsor Investigator
Principal Investigator

Deepak K. Sarpal, M.D.

Assistant Professor

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • A current Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-defined diagnosis of schizophrenia or schizoaffective disorder
  • age 18-50 years
  • at least 4 months of clozapine treatment
  • history of at least 2 failed antipsychotic trials
  • competency and willingness to sign informed consent
  • A clinically optimized dosage of clozapine, unchanged for at least 1 month, with a minimum of 150 mg/day

Exclusion Criteria

  • Serious neurologic or medical condition/treatment that impacts the brain
  • a significant risk of suicidal or homicidal behavior
  • cognitive or language limitations, or any other factor that would preclude subjects providing informed consent
  • pregnancy or postpartum (\<6 weeks after delivery or miscarriage)
  • history of treatment with electroconvulsive therapy
  • contraindications for magnetic resonance imaging (e.g., a pacemaker)
  • Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-verified moderate or severe substance use disorder, including alcohol use disorder
  • seizure disorder or prior history of seizures on clozapine
  • patients taking both bupropion and clozapine
  • prior issues with intermittent theta burst stimulation/transcranial magnetic stimulation administration

Arms & Interventions

iTBS, then Sham

Intervention: sham stimulation

iTBS, then Sham

Intervention: transcranial magnetic stimulation

Sham, then iTBS

Intervention: sham stimulation

Sham, then iTBS

Intervention: transcranial magnetic stimulation

Outcomes

Primary Outcomes

change in activation of the working memory network

Time Frame: 1 hour

Examine whether accelerated intermittent theta burst stimulation (iTBS) is associated with functional magnetic resonance imaging (fMRI)-based changes in activation of the working memory network during AX-continuous performance task engagement

change in brain functional connectivity within the prefrontal cortex

Time Frame: 1 hour

Examine changes in left dorsolateral prefrontal cortex-basal forebrain functional connectivity following adjunctive accelerated intermittent theta burst stimulation (iTBS)

Secondary Outcomes

  • explore change in functional magnetic resonance imaging (fMRI) measures versus plasma n-desmethylclozapine/clozapine ratios(1 month)

Study Sites (1)

Loading locations...

Similar Trials